{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:46:37Z","timestamp":1790289997686,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.blre.2020.100735","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T02:42:19Z","timestamp":1595472139000},"page":"100735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Loss of 5q in myeloid malignancies \u2013 A gain in understanding of biological and clinical consequences"],"prefix":"10.1016","volume":"46","author":[{"given":"Sangeetha","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100735_bb0005","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0015","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMra0803109","article-title":"Chromosomal abnormalities in cancer","volume":"359","author":"Frohling","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100735_bb0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2020.100735_bb0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2141.2000.01868.x","article-title":"Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes","volume":"108","author":"Climent","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0035","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/gcc.22377","article-title":"The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations","volume":"55","author":"Stengel","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2020.100735_bb0045","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined \u2018myelodysplastic syndrome with isolated del(5q)\u2019 in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van Den Berghe","year":"1974","journal-title":"Nature."},{"key":"10.1016\/j.blre.2020.100735_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.leu.2403189","article-title":"Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del (5q) including band q31","volume":"18","author":"Giagounidis","year":"2004","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0060","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/leu.2008.279","article-title":"Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-4608(85)90016-0","article-title":"The 5q-anomaly","volume":"17","author":"Van den Berghe","year":"1985","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2020.100735_bb0070","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.21245","article-title":"Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era","volume":"83","author":"Holtan","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100735_bb0085","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","article-title":"The 5q-syndrome","volume":"84","author":"Boultwood","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10245330410001723824","article-title":"The 5q- syndrome","volume":"9","author":"Giagounidis","year":"2004","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2020.100735_bb0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.3484837","article-title":"Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders","volume":"231","author":"Le Beau","year":"1986","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100735_bb0100","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1182\/blood.V99.12.4638","article-title":"Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome","volume":"99","author":"Boultwood","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100735_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004583","article-title":"Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31. 2 genes in de novo myelodysplastic syndromes pathogenesis","volume":"4","author":"Graubert","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2020.100735_bb0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q-syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature."},{"key":"10.1016\/j.blre.2020.100735_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2063","article-title":"A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q\u2013syndrome","volume":"16","author":"Barlow","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100735_bb0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4047","article-title":"Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9","volume":"22","author":"Schneider","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100735_bb0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ncb1858","article-title":"Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction","volume":"11","author":"Fumagalli","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.blre.2020.100735_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.beha.2010.09.006","article-title":"Genetic deletions in AML and MDS","volume":"23","author":"Ebert","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2020.100735_bb0145","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/geno.2000.6414","article-title":"Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del (5q)","volume":"71","author":"Lai","year":"2001","journal-title":"Genomics."},{"key":"10.1016\/j.blre.2020.100735_bb0155","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2011.36.1824","article-title":"Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited","volume":"30","author":"Jerez","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2020.100735_bb0165","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.18632\/oncotarget.14130","article-title":"Recurrent genetic defects on chromosome 5q in myeloid neoplasms","volume":"8","author":"Hosono","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2020.100735_bb0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del (5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100735_bb0175","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/sj.onc.1204553","article-title":"Ras\u2013GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease","volume":"20","author":"Soncini","year":"2001","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2020.100735_bb0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2020.100735_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0925-5710(96)00455-0","article-title":"Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines","volume":"63","author":"Raza","year":"1996","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2020.100735_bb0190","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.leu.2400844","article-title":"Overexpression of tumor necrosis factor (TNF)-\u03b1 and interferon (IFN)-\u03b3 by bone marrow cells from patients with myelodysplastic syndromes","volume":"11","author":"Kitagawa","year":"1997","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H","article-title":"Anti-TNF therapies in rheumatoid arthritis, Crohn\u2019s disease, sepsis, and myelodysplastic syndromes","volume":"50","author":"Raza","year":"2000","journal-title":"Micros Res Tech"},{"key":"10.1016\/j.blre.2020.100735_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000205556","article-title":"T lymphocyte subpopulations in myelodysplastic syndromes","volume":"81","author":"Carpani","year":"1989","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0205","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2020.100735_bb0210","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100735_bb0215","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"New Engl J Med."},{"key":"10.1016\/j.blre.2020.100735_bb0220","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"New Eng J Med"},{"key":"10.1016\/j.blre.2020.100735_bb0225","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0230","first-page":"37","article-title":"Lenalidomide induced durable remission in a patient with MDS\/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome","volume":"10","author":"Alshaban","year":"2018","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.blre.2020.100735_bb0235","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/sj.leu.2404398","article-title":"Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2 V617F positive, del (5)(q13q33) myelodysplastic syndrome","volume":"20","author":"Mesa","year":"2006","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0240","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.leu.2404526","article-title":"Treatment of deletion 5q acute myeloid leukemia with lenalidomide","volume":"21","author":"Lancet","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2011-02-337303","article-title":"A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: southwest oncology group study S0605","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0250","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0050035","article-title":"An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome","volume":"5","author":"Ebert","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.blre.2020.100735_bb0255","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100735_bb0260","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100735_bb0265","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100735_bb0270","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and a iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0275","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.blre.2020.100735_bb0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del (5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.blre.2020.100735_bb0285","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0290","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2007-03-079368","article-title":"The molecular signature of MDS stem cells supports a stem-cell origin of 5q\u2212 myelodysplastic syndromes","volume":"110","author":"Nilsson","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0295","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del (5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2020.100735_bb0300","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MOH.0b013e328016847a","article-title":"The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes","volume":"14","author":"Melchert","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.blre.2020.100735_bb0305","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS","volume":"28","author":"List","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0310","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.011528","article-title":"Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression","volume":"94","author":"J\u00e4dersten","year":"2009","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100735_bb0315","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2020.100735_bb0320","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0325","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2016.111","article-title":"Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)","volume":"30","author":"Mossner","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0330","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0335","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0340","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","article-title":"Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program","volume":"116","author":"Musto","year":"2010","journal-title":"Cancer."},{"issue":"21","key":"10.1016\/j.blre.2020.100735_bb0345","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1182\/blood.V120.21.3833.3833","article-title":"Azacitidine treatment for lenalidomide (LEN)-resistant myelodysplastic syndrome (MDS) with del 5q","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0350","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/leu.2013.26","article-title":"Sequential combination of azacitidine and lenalidomide in del (5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study","volume":"27","author":"Platzbecker","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100735_bb0355","series-title":"A randomized phase ii study of standard dose azacitidine alone or in combination with lenalidomide in high-risk mds with a karyotype including del(5Q)","author":"Rasmussen","year":"2018"},{"key":"10.1016\/j.blre.2020.100735_bb0360","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2011-10-382986","article-title":"L-Leucine improves the anemia and developmental defects associated with diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway","volume":"120","author":"Payne","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0365","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1182\/blood-2013-03-493809","article-title":"Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion","volume":"121","author":"Steensma","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100735_bb0370","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","article-title":"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial","volume":"23","author":"Chung","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100735_bb0375","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.1996.14.4.1320","article-title":"Phase I trial of an antisense oligonucleotide OL (1) p53 in hematologic malignancies","volume":"14","author":"Bishop","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100735_bb0380","doi-asserted-by":"crossref","first-page":"16127","DOI":"10.1073\/pnas.1311055110","article-title":"TP53 suppression promotes erythropoiesis in del (5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients","volume":"110","author":"Caceres","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2020.100735_bb0385","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100735_bb0390","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/bloodadvances.2019000537","article-title":"MMP9 inhibition increases erythropoiesis in RPS14-deficient del (5q) MDS models through suppression of TGF-\u03b2 pathways","volume":"3","author":"Youn","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100735_bb0395","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41556-020-0497-9","article-title":"Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome","volume":"22","author":"Martinez-H\u00f8yer","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.blre.2020.100735_bb0400","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2020.100735_bb0405","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2017.11.017","article-title":"Allogeneic stem cell transplantation for Myelodysplastic syndrome patients with a 5q deletion","volume":"24","author":"Garderet","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:26Z","timestamp":1759436786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":81,"alternative-id":["S0268960X20300850"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100735","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of 5q in myeloid malignancies \u2013 A gain in understanding of biological and clinical consequences","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100735"}}